Infectious Disease Topics
RSSArticles
-
Treatment of Pulmonary Mycobacterium avium Infection: Failure Is Common
Current treatment regimens for pulmonary Mycobacterium avium infection leave a great deal to be desired.
-
Immunohistochemistry and Diagnosis of Viral Diseases
Researchers reviewed five years of cases at an academic medical center’s pathology department for the use of immunohistochemistry to detect CMV, HSV-1, HSV-2, varicella zoster virus, adenovirus, or polyomavirus. Of 957 cases, 134 were positive. Viral cytopathic effect (CPE) was present on hematoxylin and eosin staining in 75% of the IHC+ cases. No changes in clinical care occurred in any of the IHC+ cases in which viral CPE was absent.
-
Mice, Mutations, and Microcephaly: The Evolving Pathogenesis of Congenital Zika Syndrome
Approximately five years ago, a single gene mutation altered Zika virus, making it able to target neuronal progenitor cells and cause what we now know as congenital Zika syndrome with microcephaly and ocular abnormalities.
-
Antibiotics and Adverse Events: Doctors, Do No Harm
A retrospective study found that among 1,488 hospitalized patients who received an antibiotic, 298 (20%) experienced at least one antibiotic-associated adverse drug event. Furthermore, 287 (19%) of the antibiotic regimens were not clinically indicated, and 56 (20%) of these were associated with an adverse drug event.
-
Delafloxacin (Baxdela®)
Delafloxacin is a new broad-spectrum fluoroquinolone that was approved by the U.S. Food and Drug Administration in June 2017 for acute bacterial skin and skin structure infections.
-
Infectious Disease Alert Updates
Corporate Antibiotic Stewardship; Hypervirulence Meets Antibiotic Resistance — A Lethal Combination; Glue Masquerading as an Aortic Root Abscess; Molecular Diagnostic Coup
-
California and Coccidioidomycosis: Be Careful About the Air You Breathe
Cases of coccidioidomycosis significantly increased in 2016.
-
Delafloxacin (Baxdela®)
Delafloxacin is a new broad-spectrum fluoroquinolone that was approved by the U.S. Food and Drug Administration in June 2017 for acute bacterial skin and skin structure infections.
-
Fungal Endophthalmitis: Another Risk Associated With Intravenous Drug Use
A retrospective cohort study found that endogenous fungal endophthalmitis is associated with intravenous drug use and frequently results in poor visual outcomes despite appropriate surgical and antifungal therapy.
-
Rheumatic Heart Disease — The Global Situation
With advances in access to good medical care, the global burden of rheumatic heart disease is declining. However, there still is significant disease in resource-limited regions of the world.